问医生,享健康!
李学松
主任医师
北京大学第一医院
泌尿外科

李学松,男,北京大学第一医院泌尿外科主任医师,教授,博士生导师,科室行政副主任。专业方向为泌尿系肿瘤和输尿管疾病的开放及微创治疗,尤其擅长复杂疑难的肾脏、输尿管及膀胱修复重建及泌尿系肿瘤的腹腔镜和达芬奇机器人手术,创新改良多项手术技术,是中国上尿路修复领域年青一代的开拓者和领军人物。社会任职北京大学泌尿外科医师培训学院副院长中华医学会泌尿外科分会(CUA)泌尿男科工程学组委员中华医学会泌尿外科分会(CUA)青年委员中华医学会泌尿外科分会(CUA)青年委员会微创学组副组长中国医师协会泌尿外科医师分会(CUDA)委员兼副总干事CUDA-UTUC协作组秘书长北京医学会泌尿外科学分会青年委员会副主任委员北京医学会泌尿外科学分会尿路修复及重建学组副组长中国医促会泌尿生殖委员会委员泌尿外科疾病国际共识(SIU-ICUD)咨询委员会委员中国研究型医院泌尿外科青委副主任委员北京健康促进会泌尿外科专业委员会委员中国机器人医师分会泌外学组委员《CurrentOpineinUrology中文版》编辑部主任兼副主编《泌尿外科杂志(电子版)》副主编《现代泌尿外科杂志》编委《TranslationalAndrologyandUrology》编委《中华泌尿外科杂志》通讯编委《Andrology》审稿专家《AnnalsofSurgicalOncology》审稿专家《Oncotarget》审稿专家《Urology》审稿专家《CanadianJournalofurology》审稿专家《ClinicalGenitourinaryCancer》审稿专家《ChineseJournalofCancerResearch(CJCR)》审稿专家《ChinesemedicalJournal》审稿专家《CurrentDrugMetabolism》审稿专家获奖荣誉2014,2015,2016年度中国医师百强榜膀胱癌专业上榜专家2015年获得第一届郭应禄泌尿外科青年医师奖2017年获得华夏医学科技奖二等奖2017年获得中华医学科技奖三等奖2018年获得教育部高等学校科学研究优秀成果奖(教育部奖)二等奖2018年北京市科技进步三等奖2018年转化实用新型专利1项2019年获得世界华人泌尿外科学会新星奖2019年获得国之名医优秀风范奖科研成果1、手术改良和创新基于多年手术经验,总结北京大学泌尿外科研究所(InstituteofUrologyPekingUniversity,IUPU)手术技术,创新改良多项手术技术。在肿瘤领域,创新使用包括针对腹侧肾肿瘤的腹腔镜腹膜后肾肿瘤内部悬吊技术,针对肾门型肾肿瘤的腹腔镜部分切术中的环形缝合技术,针对输尿管肿瘤的完全腹腔镜下肾输尿管全长切除术及改良袖状切除技术,针对浸润性膀胱癌的IUPU改良回肠原位新膀胱术等多项手术技术,在保证手术效果的同时使得泌尿外科肿瘤手术微创化、简单化、实用化。在上尿路重建领域,总结北京大学泌尿所IUPU回肠代输尿管术等手术经验,创新使用IUPU改良经腹腹腔镜肾盂成形术、IUPU回肠代输尿管联合膀胱瓣腰肌悬吊技术、针对巨输尿管使用IUPU经腹腹腔镜输尿管体外裁剪、乳头再植的改良术式等多项手术技术,在国内泌尿外科领域中推动输尿管重建手术的微创化、标准化、个体化。2、泌尿系肿瘤的临床和基础研究基于多年对泌尿系肿瘤的研究,在肾癌、尿路上皮癌临床预后特点、诊断、治疗及分子机制探索中做了大量的工作,并在多领域多维度进行了深入的探索。在上尿路尿路上皮癌(UTUC)研究中,首次描述了中国北方地区大型UTUC队列临床病理及预后特点,并调查发现了马兜铃酸相关UTUC的比例、临床预后特点;首次探索了大规模UTUC患者肿瘤组织肿瘤相关基因启动子甲基化状态,及临床相关性等。近期科研重点为从尿液中筛查泌尿系肿瘤的分子标志物,研究结果具有非常好的应用前景。在肿瘤表观修饰研究方面,首次发现肾癌和尿路上皮癌5hmC水平整体降低;5hmC变化主要集中在基因体区域,引起了该区域的过度甲基化。实验结果表明5hmC在肾癌和尿路上皮癌中的重编程更有可能是一种驱动力。以vitaminC来重建细胞内DNA羟甲基化水平,预期达到辅助靶向治疗的作用。在中英文杂志发表了二百余篇论文,第一或通讯作者发表SCI论文70余篇。参编或编译泌尿外科专业书籍14部,主译3部,主编1部。代表性文章(#第一作者;*通讯作者)SCI文章:1.BaoGuan#,ShiyingTang#,YonghaoZhan#,YifanLi,DongFang,DingPeng,YanqingGong,ShimingHe,LeiZhang,KunlinYang,GengyanXiong,LiboLiu,QunHe,XuesongLi*,LiqunZhou*.Prognosticperformanceofthe1973and2004WHOgradingclassificationinuppertracturothelialcarcinoma.UrolOncol.2019.(IF3.397)2.YifanLi#,BaoGuan#,JingtaoLiu#,ZhongyuanZhang,ShimingHe,YonghaoZhan,BoxingSu,HaiboHan,XiaochunZhang,BoqingWang,XuesongLi*,LiqunZhou*,WeiZhao*.MicroRNA-200bisdownregulatedandsuppressesmetastasisbytargetingLAMA4inrenalcellcarcinoma.EBioMedicine.2019.(IF6.183)3.YifanLi#,ShimingHe#,AnbangHe,BaoGuan,GuangzheGe,YonghaoZhan,YucaiWu,YanqingGong,DingPeng,ZhengqingBao,XuesongLi*,LiqunZhou*.Identificationofplasmasecretedphosphoprotein1asanovelbiomarkerforuppertracturothelialcarcinomas.BiomedPharmacother.2019;113:108744.(IF3.457)4.WenlongZhong#,PengHong#,GuangpuDing#,KunlinYang,XuesongLi*,JunshengBao,GuochangBao,LiangCui,ChangpingMen,ZheLi,PengZhang,NingChuandLiqunZhou*.Technicalconsiderationsandoutcomesforilealureterreplacement:aretrospectivestudyinChina.BMCSurgery,2019;19:9.(IF1.692)5.PengHong#,ZiaoLi#,DongdongZhu#,LiyanZhuang,KunlinYang,HanHao,XuesongLi*,LiqunZhou*.ASimpleModificationfortheUsageofFlexibleCystoscopeinModifiedLaparoscopicPyeloplastyforUreteropelvicJunctionObstructionwithRenalCalculi:AFlexibleGuidingTube.UrolInt.2019;102(3):262-268.(IF1.508)6.YifanLi#,DongFang#,ZhengqingBao#,AnbangHe,BaoGuan,ShimingHe,YonghaoZhan,YanqingGong,XuesongLi*,LiqunZhou*.Highaspartatetransaminase/alaninetransaminaseratiopredictspoorprognosisinpatientswithlocalizeduppertracturothelialcancer:apropensityscore-matchedstudyinalargeChinesecenter.OncoTargetsTher,2019;12:2635-2648.(IF2.656)7.PengHong,YukunCai,ZiaoLi,ShuboFan,KunlinYang,HanHao,QunHe,XuesongLi*,LiqunZhou*.ModifiedLaparoscopicPartialUreterectomyforAdultUreteralFibroepithelialPolyp:TechniqueandInitialExperience.UrolInt.2018;102(1):13-19.(IF1.508)8.ZhuoJia#,YanqingGong#,CuijianZhang,ZhengqingBao,XuesongLi*,HanHao,GengyanXiong,LeiZhang,DongFang,ZhisongHe,LiqunZhou*.Segmentalureterectomycanbeperformedsafelyinpatientswithurothelialcarcinomaofdistalureter.CanUrolAssocJ.2018;13(7).(IF1.179)9.YifanLi#,YanqingGong#,XianghuiNing,DingPeng,LiboLiu,ShimingHe,KanGong,CuijianZhang*,XuesongLi*andLiqunZhou*.DownregulationofCLDN7duetopromoterhypermethylationisassociatedwithhumanclearcellrenalcellcarcinomaprogressionandpoorprognosis.JExpClinCancerRes.2018;37(1):276.(IF6.217)10.YonghaoZhan,ZhicongChen,YifanLi,AnbangHe,ShimingHe,YanqingGong,XuesongLi*andLiqunZhou*.Longnon-codingRNADANCRpromotesmalignantphenotypesofbladdercancercellsbymodulatingthemiR-149/MSI2axisasaceRNA.JExpClinCancerRes.2018;37(1):273.(IF6.217)11.AnbangHe#,ShimingHe#,XuesongLi*,LiqunZhou*.ZFAS1:AnovelvitaloncogeniclncRNAinmultiplehumancancers.CellProliferation.2018;66(4):e12513.(IF4.936)12.DingPeng,GuangzheGe,ZhengzhengXu,QinMa,YueShi,YuanyuanZhou,YanqingGong,GengyanXiong,CuijianZhang,ShimingHe,ZhisongHe,XuesongLi*,WeiminCi*andLiqunZhou*.DiagnosticandprognosticbiomarkersofcommonurologicalcancersbasedonaberrantDNAmethylation.Epigenomics.2018;10(9):1189-1199.(IF4.979)13.ZhicongChen#,YonghaoZhan#,JieshanChi#,ShuyuanGuo#,XinliangZhong,AnbangHe,JianrongZheng,YanqingGong,XuesongLi*,LiqunZhou*.UsingmicroRNAsasNovelPredictorsofUrologicCancerSurvival:AnIntegratedAnalysis.EBioMedicine.2018;34:94-107.(IF6.183)14.GuangzheGe#,DingPeng#,ZiyingXu#,BaoGuan,ZijuanXin,QunHe,YuanyuanZhou,XuesongLi*,LiqunZhou*andWeiminCi*.Restorationof5-hydroxymethylcytosinebyascorbateblockskidneytumourgrowth.EMBOReports.2018;19(8):e45401.(IF8.749)15.DingPeng,GuangzheGe,YanqingGong,YonghaoZhan,ShimingHe,BaoGuan,YifanLi,ZiyingXu,HanHao,ZhisongHeGengyanXiong,CuijianZhang,YueShi,YuanyuanZhou,WeiminCi*,XuesongLi*andLiqunZhou*.VitaminCincreases5-hydroxymethylcytosinelevelandinhibitsthegrowthofbladdercancer.ClinEpigenetics.2018;10(1):94.(IF6.091)16.BaoGuan#,YunchaoXing#,GengyanXiong#,ZhenpengCao,DongFang,YifanLi,YonghaoZhan,DingPeng,LiboLiu,XuesongLi*andLiqunZhou*.Predictivevalueofgenemethylationforsecondrecurrencefollowingsurgicaltreatmentoffirstbladderrecurrenceofaprimaryupper-tracturothelialcarcinoma.OncologyLetters.2018;15(6):9397-9405.(IF1.664)17.DingPeng#,CuijianZhang#,YanqingGong*,HanHao,BaoGuan,XuesongLi*andLiqunZhou*.PrognosticsignificanceofHALP(hemoglobin,albumin,lymphocyteandplatelet)inpatientswithbladdercancerafterradicalcystectomy.ScientificReports.2018;8:794.(IF4.122)18.DingPeng#,Cui-jianZhang#,QiTang,LeiZhang,Kai-weiYang,Xiao-tengYu,YanqingGong,Xue-songLi*,Zhi-songHeandLi-qunZhou*.Prognosticsignificanceofthecombinationofpreoperativehemoglobinandalbuminlevelsandlymphocyteandplateletcounts(HALP)inpatientswithrenalcellcarcinomaafternephrectomy.BMCUrol,2018,18:20.(IF1.792)19.DongFang#,ShimingHe#,GengyanXiong#,NirmishSingla,ZhenpengCao,LeiZhang,XuesongLi*andLiqunZhou*.Comparisonofclinicopathologiccharacteristics,epigeneticbiomarkersandprognosisbetweenrenalpelvicandureteraltumorsinuppertracturothelialcarcinoma.BMCUrol.2018;18(1):22.(IF1.792)20.BaoGuan#,YicongDu#,XiaohongSu#,ZhenpengCao,YifanLi,YonghaoZhan,DingPeng,GengyanXiong,DongFang,YiDing,ShimingHe,YanqingGong,QunHe,XuesongLi*andLiqunZhou*.Positiveurinaryfluorescenceinsituhybridizationindicatespoorprognosisinpatientswithuppertracturothelialcarcinoma.Oncotarget.2018;9(18):14652-14660.21.Run-QiGuo#,Geng-YanXiong#,Kai-WeiYang,LeiZhang,Shi-MingHe,Yan-QingGong,,QunHe,Xue-YingLi,Zi-ChengWang,Zhen-QingBao,Xue-SongLi*,KaiZhang,Li-QunZhou*.Detectionofurothelialcarcinoma,uppertracturothelialcarcinoma,bladdercarcinoma,andurothelialcarcinomawithgrosshematuriausingselectedurine-DNAmethylationbiomarkers:Aprospective,single-centerstudy.UrolOncol.2018;36(7):342.e15-342.e23.(IF3.397)22.ShiyingTang,HanHao,DongFang,WeiZheng,PengGe,XiaohongSu,QunHe,XinyuYang,QiShen,XuesongLi*,WeiYu,JianLin,LiqunZhou.Prostatecancerincidentallydiscoveredatthetimeofradicalcystoprostatectomydoesnotdecreaseoverallsurvival:ResultsfromalargeChinesemedicalcenter.IntBrazJUrol.2018;44(2):258-266.(IF0.976)23.PengHong,GuangpuDing,DongdongZhu,KunlinYang,JinhongPan*,XuesongLi*,ZhipengChen,LeiZhang,QiTang,HanHao,ZhansongZhouandLiqunZhou.Head-to-HeadComparisonofModifiedLaparoscopicPyeloplastyandRobot-AssistedPyeloplastyforUreteropelvicJunctionObstructioninChina.UrolInt.2018;101(3):337-344.(IF1.508)24.GengyanXiong#,LinYao#,PengHong#,LiYang,WeiminCi,LiboLiu,QunHe,KanGong,XuesongLi*andLiqunZhou*.Aristolochicacidcontainingherbsinducegender-relatedoncologicaldifferencesinuppertracturothelialcarcinomapatients.CancerManagRes.2018;10:6627-6639.(IF3.702)25.WenlongZhong#,LinYao#,HaoranCui,KunlinYang,GangWang,TaoXu,XiongjunYe,XuesongLi*,LiqunZhou*.Laparoscopicureteralreimplantationwithextracorporealtailoringanddirectnippleureteroneocystostomyforadultobstructivemegaureter:long-termoutcomesandcomparisontoopenprocedure.IntUrolNephrol.2017;49(11):1973-1978.(IF1.692)26.ShiyingTang#,GuochenNiu#,DongFang,ZiguangYan,BihuiZhang,XuesongLi*,MinYang*,LiqunZhou*.Thediagnosisandendovasculartherapyofrenalarteryaneurysm:A32-patientcasereport.Medicine(Baltimore).2017;96(47):e8615.(IF2.028)27.WenlongZhong#,YicongDu#,KunlinYang,StevenMeng,RongchengLin,XuesongLi*,LiyanZhuang,LinCai,HaoranCui,ZhisongHe,andLiqunZhou.IlealUreterReplacementCombinedwithBoariFlap-PsoasHitchtoTreatFull-LengthUreteralDefects:TechniqueandInitialExperience.Urology.2017;108:201-206.(IF2.3)28.Zhen?PengCao,BaoGuan,Guang?ZhiZhao,DongFang,Geng?YanXiong,XuesongLi*,Li?QunZhou.ValidationofthePretreatmentNeutrophil?to?LymphocyteRatioasaPrognosticFactorinaLargeCohortofChinesePatientswithUpperTractUrothelialCarcinoma.ChinMedJ(Engl).2017,130(17):2063-2068.(IF1.596)29.YonghaoZhan,YifanLi,BaoGuan,ZichengWang,DingPeng,ZhicongChen,AnbangHe,ShimingHe,YanqingGong,XuesongLi*andLiqunZhou*.Longnon-codingRNAHNF1A-AS1promotesproliferationandsuppressesapoptosisofbladdercancercellsthroughupregulatingBcl-2.Oncotarget.2017;8(44):76656-76665.(IF5.168)30.YonghaoZhan#,YifanLi#,BaoGuan#,XiaoyingChen,ZhicongChen,AnbangHe,ShimingHe,YanqingGong,DingPeng,YuchenLiu,ZhimingCai,XuesongLi*andLiqunZhou*.Increasedoflongnon-codingRNACCEPRisassociatedwithpoorprognosisandpromotestumorigenesisinurothelialbladdercarcinoma.Oncotarget.2017;8(27):44326-44334.(IF5.168)31.XiaohongSu#,HanHao#,XuesongLi*,ZhisongHe,KanGong,CuijianZhang,LinCai,QianZhang,LinYao,YiDing,YanqingGong,DongFang,ZhengZhangandLiqunZhou*.Fluorescenceinsituhybridizationstatusofvoidedurinepredictsinvasiveandhigh-gradeuppertracturothelialcarcinoma.Oncotarget.2017;8(16):26106-26111.(IF5.168)32.WenlongZhong#,RongchengLin#,LeiZhang,ChengyueJin,XuesongLi*,QunHe,KanGong,ZhisongHe,LiqunZhou*.Clinicopathologiccharacteristics,therapyandoutcomesofpatientswithprimaryureteralsmallcellcarcinoma:acaseseriesandsystematicreviewoftheliterature.OncoTargetsTher.2017;10:4105-4111.(IF2.656)33.WenlongZhong#,LeiZhang#,JiajianMa,ShanShao,RongchengLin,XuesongLi*,GengyanXiong,DongFang,LiqunZhou*.Impactofaristolochicacidexposureononcologicoutcomesofuppertracturothelialcarcinomaafterradicalnephroureterectomy.OncoTargetsTher.2017;10:5775-5782.(IF2.656)34.WenlongZhong,YicongDu,LeiZhang,XuesongLi*,CuijianZhang,DongFang,GengyanXiong,ZhisongHe,andLiqunZhou*.TheApplicationofInternalSuspensionTechniqueinRetroperitonealLaparoscopicPartialNephrectomyforRenalVentralTumors.BioMedResInt.2017;2017(5i):1-7.(IF2.583)35.YunchaoXing#,GengyanXiong#,DongFang,XinyuYang,XuesongLi*,LiqunZhou*.PrognosticValueofGeneMethylationandClinicalFactorsinNon-Muscle-InvasiveUpperTractUrothelialCarcinomaAfterRadicalNephroureterectomy.ClinGenitourinCancer.2016;14(4):e371-e378.(IF2.539)36.PeiLiu,XiaohongSu,GengyanXiong,XuesongLi*,LiqunZhou.DiagnosticUreteroscopyforUpperTractUrothelialCarcinomaisIndependentlyAssociatedwithIntravesicalRecurrenceafterRadicalNephroureterectomy.IntBrazJUrol.2016;42(6):1129-1135.(IF0.976)37.XiaohongSu#,DongFang#,LeiZhang,GengyanXiong,HanHao,GuangzhiZhao,KunlinYang,YunchaoXing,XuesongLi*,LiqunZhou*.Treatmentstrategiesforuppertracturothelialcarcinoma(UTUC)ofasolitarykidney:asingle-institutionalanalysisof61cases.IntUrolNephrol.2016;48(10):1601-1608.(IF1.692)38.LeiZhang,DongFang,XuesongLi*,LinYao,GengyanXiong,ZhisongHe,andLiqunZhou*.TransperitonealSubcostalAccessforUrologicLaparoscopy:ExperienceofaLargeChineseCenter.BioMedResInt.2016;2016(1):1-5.(IF2.583)39.XiaohongSu,DongFang,XuesongLi*,GengyanXiong,LeiZhang,HanHao,YanqingGong,ZhengZhang,andLiqunZhou*.TheInfluenceofTumorSizeonOncologicOutcomesforPatientswithUpperTractUrothelialCarcinomaafterRadicalNephroureterectomy.BioMedResInt.2016;2016:1-7.(IF2.583).40.LeiZhang,LinYao,XuesongLi*,MichaelA.S.Jewett,ZhisongHe,LiqunZhou*.Naturalhistoryofrenalcellcarcinoma:Animmunohistochemicalanalysisofgrowthrateinpatientswithdelayedtreatment.JFormosMedAssoc.2015;115(6):463-469.(IF2.452)41.QiTang#,GengyanXiong#,XuesongLi*,DongFang,ChenguangXi,LeiZhang,KaiweiYang,LinYao,CuijianZhang,WeiYu,QunHe,KanGong,ZhisongHe,LiqunZhou*.Theprognosticimpactofsquamousandglandulardifferentiationforuppertracturothelialcarcinomapatientsafterradicalnephroureterectomy.WorldJUrol.2015;34(6):871-877.(IF2.981)42.PeiLiu#,DongFang#,GengyanXiong,KaiweiYang,LeiZhang,LinYao,CuijianZhang,XuesongLi*,ZhisongHe,LiqunZhou*.ANovelandSimpleModificationforManagementofDistalUreterDuringLaparoscopicNephroureterectomyWithoutPatientRepositioning:ABulldogClampTechniqueandDeionofModifiedPortPlacement.JEndourol.2015;30(2):195-200.(IF2.038)43.DongFang#,PeiLiu#,XuesongLi*,GengyanXiong,LeiZhang,NirmishSingla,GuangzhiZhao,QunHe,ZhisongHeandLiqunZhou*.Characteristicsandtreatmentoutcomesofpan-urothelialcellcarcinoma:adeiveanalysisof45patients.ScientificReports.2015;5(1):18014.(IF4.122)44.YanqingGong,WeiQiu,XianghuiNing,XinyuYang,LiboLiu,ZichengWang,JianLin,XuesongLi*,YingluGuo*.CCDC34isup-regulatedinbladdercancerandregulatesbladdercancercellproliferation,apoptosisandmigration.Oncotarget.2015;6(28):25856-25867.(IF5.168)45.KunlinYang#,LinCai#,LinYao,ZhengZhang,CuijianZhang,XinWang,JianqiangTang*,XuesongLi*,ZhisongHeandLiqunZhou.Laparoscopictotalpelvicexenterationforpelvicmalignancies:thetechniqueandshort-timeoutcomeof11cases.WorldJSurgOncol.2015;13(1):301.(IF1.792)46.ZhengZhang#,DongFang#,XiaopengChen,XuesongLi*,GengyanXiong,LeiZhang,QunHeandLiqunZhou*.Predictiveroleofpreoperativehydronephrosisonpoorpathologicaloutcomesandprognosisinuppertracturothelialcarcinomapatients:Experiencefromanationwidehigh-volumecenterinChina.OncolLett.2015;10(5):3113-3122.(IF1.664)47.XiaotengYu#,GangGuo#,XuesongLi#,CuijianZhang,LihuaHuang,DongFang,YiSong,XuZhang,andLiqunZhou*.RetrospectiveAnalysisoftheEfficacyandSafetyofSorafenibinChinesePatientswithMetastaticRenalCellCarcinomaandPrognosticFactorsRelatedtoOverallSurvival.Medicine(Baltimore).2015;94(34):e1361.(IF2.028)48.LeiZhang,XuesongLi*,LiqunZhou*.NaturalHistoryofSmallRenalMasses.ChinMedJ(Engl).2015;128(9):1232–1237.(IF1.596)49.GengyanXiong#,JinLiu#,QiTang,YuFan,DongFang,KaiweiYang1,FengXie,MinZhang,LeiZhang,LiboLiu,CuijianZhang,LinYao,LiYang,WeiminCi,WeiZhao,YanqingGong,QunHe,KanGong,ZhisongHe,GangWang,XuesongLi*#,YingluGuoandLiqunZhou#.Prognosticandpredictivevalueofepigeneticbiomarkersandclinicalfactorsinuppertracturothelialcarcinoma.Epigenomics.2015;7(5):733-744.(IF4.979)50.DongFang#,LeiZhang#,XuesongLi*,WeiYu,NirmishSingla,GuangzhiZhao,GengyanXiong,YiSong,QunHe,ZhisongHe,andLiqunZhou*.PresenceofConcomitantNon-muscle-invasiveBladderCancerinChinesePatientswithUpperTractUrothelialCarcinoma:RiskFactors,Characteristics,andPredictiveValue.AnnSurgOncol.2015;22(8):2789-2798.(IF3.857)51.BentaoShi#,BoxingSu#,DongFang,YuanTang,GengyanXiong,ZhongqiangGuo,QunHe,XinyuYang,WeiZhao,YingluGuo,XuesongLi*andLiqunZhou*.HighofKPNA2definespoorprognosisinpatientswithuppertracturothelialcarcinomatreatedwithradicalnephroureterectomy.BMCCancer.2015;15(1):380.(IF3.288)52.DongFang#,GengyanXiong#,XuesongLi*,YongmingKang,LeiZhang,GuangzhiZhao,XiaopengChen,LinYao,XiaoyuZhang,WeiYu,KanGong,YiSong,QunHe,ZhisongHe,LiqunZhou*,YingluGuo.Incidence,characteristics,treatmentstrategies,andoncologicoutcomesofsynchronousbilateraluppertracturothelialcarcinomaintheChinesepopulation.UrologicOncology.2015;33(2):66.e1-.e11.(IF3.397)53.LeiZhang#,GengyanXiong#,DongFang,XuesongLi*,JinLiu,WeiminCi,WeiZhao,NirmishSingla,ZhisongHeandLiqunZhou*.Contralateraluppertracturothelialcarcinomaafternephroureterectomy:thepredictiveroleofDNAmethylation.JExpClinCancerRes.2015;34(1):5.(IF6.217)54.KunlinYang#,LinYao#,XuesongLi*,CuijianZhang,TianyuWang,LeiZhang,DongFang,ZhisongHe,andLiqunZhou*.Amodifiedsuturetechniquefortransperitoneallaparoscopicdismemberedpyeloplastyofpelviuretericjunctionobstruction.Urology.2015;85(1):263-267.(IF2.3)55.LeiZhang,WenshiYin,LinYao,XuesongLi*,DongFang,DaRen,ZhongyuanZhang,YuFan,QunHe,WeiminCi,ZhisongHe,andLiqunZhou*.GrowthPatternofClearCellRenalCellCarcinomainPatientswithDelayedSurgicalIntervention:FastGrowthRateCorrelateswithHighGradeandMayResultinPoorPrognosis.BioMedResInt.2015;2015(4):598134-598138.(IF2.583)56.QiTang,YiSong,XuesongLi*,MaxwellMeng,QianZhang,JinWang,ZhisongHe,andLiqunZhou*.PrognosticOutcomesandRiskFactorsforPatientswithRenalCellCarcinomaandVenousTumorThrombusafterRadicalNephrectomyandThrombectomy:ThePrognosticSignificanceofVenousTumorThrombusLevel.BioMedResInt.2015;2015:163423.(IF2.583)57.XiaotengYu,BingWang,XuesongLi*,GangLin,CuijianZhang,YangYang,DongFang,YiSong,ZhisongHeandLiqunZhou*.TheSignificanceofMetastasectomyinPatientswithMetastaticRenalCellCarcinomaintheEraofTargetedTherapy.BioMedResInt.2015;2015:176373.(IF2.583)58.ZhongqiangGuo,JinLiu,LianZhang,BoxingSu,YunchaoXing,QunHe,WeiminCi,XuesongLi*andLiqunZhou*.KCNJ1inhibitstumorproliferationandmetastasisandisaprognosticfactorinclearcellrenalcellcarcinoma.TumourBiol.2014;36(2):1251-1259.(IF3.65)59.DongFang#,LeiZhang#,XuesongLi*,GengyanXiong,XiaopengChen,WenkeHan,ZhisongHe,LiqunZhou*.Riskfactorsandtreatmentoutcomesofnewcontralateralupperurinaryurothelialcarcinomaafternephroureterectomy:theexperiencesofalargeChinesecenter.JCancerResClinOncol.2014;140(3):477-485.(IF3.282)60.DongFang,QifuZhang,XuesongLi*,ChengQian,GengyanXiong,LeiZhang,XiaopengChen,XiaoyuZhang,WeiYu,ZhisongHe,andLiqunZhou*.NomogrampredictingrenalinsufficiencyafternephroureterectomyforuppertracturothelialcarcinomaintheChinesepopulation:exclusionofineligiblecandidatesforadjuvantchemotherapy.BioMedResInt.2014;2014(3):529186-10.(IF2.583)61.XuesongLi*,DongFang,MatthewR.Cooperberg*,JaredM.Whitson,TomF.Lue,LiqunZhou,KatsutoShinohara.Long-termfollow-upofInternationalProstateSymptomScore(IPSS)inmenfollowingprostatebrachytherapy.WorldJUrol.2013;32(4):1061-1066.(IF2.981)62.GengyanXiong,XiaopengChen,XuesongLi*,DongFang,LuxiaZhang,LiYang,LeiZhang,LinYao,ZhisongHe,LiqunZhou*.PrenceandfactorsassociatedwithbaselinechronickidneydiseaseinChina:a10-yearstudyof785upperurinarytracturothelialcarcinomapatients.JFormosMedAssoc.2013;113(8):521-526.(IF2.452)63.RuiHe#,WeiYu#,XuesongLi*,LinYao,ZhisongHe,andLiqunZhou*.Laparoscopicureteralreimplantationwithextracorporealtailoringanddirectnippleureteroneocystostomyforadultobstructedmegaureter:anoveltechnique.Urology.2013;82(5):1171-1174.(IF2.3)64.Xue-SongLi,LinYao,KanGong,WeiYu,QunHe,Li-QunZhou,Zhi-SongHe*.Growthpatternofrenalcellcarcinoma(RCC)inpatientswithdelayedsurgicalintervention.JCancerResClinOncol.2012;138:269–274.(IF3.282)65.HongjianZhu,ChengShen,XuesongLi*,XurenXiao,XianglongChen,QingjiangZhang,HuaWang,ZhisongHe,LiqunZhou.Laparoscopicpyeloplasty:acomparisonbetweenthetransperitonealandretroperitonealapproachduringthelearningcurve.UrolInt.2012;90(2):130-135.(IF1.508)66.CuijianZhang,XuesongLi*,HanHao,WeiYu,ZhisongHeandLiqunZhou*.Thecorrelationbetweensizeofrenalcellcarcinomaanditshistopathologicalcharacteristics:asinglecenterstudyof1867renalcellcarcinomacases.BJUInt.2012;110(11PtB):E481-E485.(IF4.688)67.CuijianZhang,XuesongLi*,ZhisongHe,YunxiangXiao,ShuqingLi,andLiqunZhou.Squamouscellcarcinomaoftheenlargedprostaticutricleinanadult.Urology.2012;79(2):e23-e24.(IF2.3)68.XiaopengChen,XuesongLi*,MauriceM.Garcia,KanGong,YiSong,ZhisongHe,andLiqunZhou*.PrognosticfactorsinChinesepatientswithpenileinvasivesquamouscellcarcinoma.JAndrol.2012;33(6):1276-1281.69.RuiHe,XinyuYang,XuesongLi*,ZhisongHe,andLiqunZhou.Cysticschwannomaofaseminalvesicle.JAndrol.2012;33(5):798-800.70.WeiZheng,XuesongLi*,GangSong,ZhengZhang,WeiYu,KanGong,YiSong,QianZhang,ZhisongHe,YingluGuo,LiqunZhou*.Comparisonoflaparoscopicandopencystectomyforbladdercancer:asinglecenterof110casesreport.TranslAndrolUrol.2012;1(1):4-8.中文文章:1.李世强,智静涛,武利兵,张锋,吴宪伟,李学松*.内镜治疗前列腺增生与尿道狭窄后并发感染的临床特征与治疗效果研究[J].中国性科学,2019,28(2):27-29.2.李学松,洪鹏,丁光璞,等.经腹完全腹腔镜肾输尿管全长切除术的关键技术总结(附光盘)[J].现代泌尿外科杂志,2018,23(10):728-731.3.鲍正清#,方冬#,纪永鹏,李学松*,周利群*.阴茎癌腹股沟淋巴结清扫腹腔镜手术的新进展[J].现代泌尿外科杂志,2018,23(4):309-312,316.4.余霄腾,张崔建,彭鼎,林榕城,唐琦,杨恺惟,张争,何志嵩,李学松*,周利群*.系统免疫炎症指数对于肾透明细胞癌患者术后预后的意义[J].中华临床医师杂志(电子版),2018,12(9):483-487.5.钟文龙,李学松*,周利群*.内部悬吊技术在腹侧肾肿瘤后腹腔镜下肾部分切除术中的应用[J].微创泌尿外科杂志,2017,6(5):6.关豹,曹振朋,彭鼎,李一帆,詹永豪,何世明,巩艳青,方冬,张雷,熊耕砚,李学松*,周利群*.上尿路尿路上皮癌患者膀胱复发灶的危险因素分析[J].中华泌尿外科杂志,2017,38(12):896-900.7.曹振朋,关豹,方冬,熊耕砚,何世明,李学松*,周利群.年轻上尿路尿路上皮癌患者的临床病理和预后特征[J].现代泌尿外科杂志,2017,22(9):661-665.8.唐世英,郝瀚,方冬,郑卫,彭东,詹永豪,鲍正清,李学松*,周利群*.保留女性生殖器官膀胱切除术的临床预后分析(附87例报告)[J].临床泌尿外科杂志,2017,32(10):741-745,750.9.关豹,曹振朋,彭鼎,李一帆,詹永豪,刘漓波,何世明,熊耕砚,李学松*,周利群*.T2N0M0期上尿路尿路上皮癌患者预后相关因素分析:单中心235例患者回顾性研究[J].北京大学学报(医学版),2017,49(4):603-607.10.洪鹏,李一帆,方冬,,郭润碛,钟文龙,郝瀚,郑卫,葛鹏,巩艳青,张争*,李学松*,林健,周利群.体质指数对于根治性膀胱全切患者的临床特征和治疗结局的影响[J].肿瘤学杂志,2017,23(7):567-573.11.朱雨泽,张雷,方冬,李学松*,周利群*.双肾嗜酸细胞瘤1例报告并文献复习[J].现代泌尿外科杂志,2016,21(9):734-735.12.刘瑾,熊耕砚,唐琦,方冬,李学松*,周利群*.上尿路尿路上皮癌中RASSF1A基因启动子区域的甲基化状态及其临床意义[J].北京大学学报(医学版),2016,48(4):571-578.13.苏晓鸿,方冬,张雷,熊耕砚,郝瀚,赵广智,杨昆霖,李学松*,周利群*.孤立肾上尿路尿路上皮癌61例临床诊疗分析[J].临床泌尿外科杂志,2016,31(12):1078-1082,1087.14.邢云超,熊耕砚,方东,张争,蔡林,张雷,何志嵩,李学松*,周利群*.上尿路尿路上皮癌术前预后相关因素分析及初步风险分层模型构建[J].北京大学学报(医学版),2016,48(6):1032-1037.15.钟文龙#,郝瀚#,苏晓鸿,方冬,郑卫,葛鹏,李学松*,周利群*.根治性膀胱全切术后患者临床病理及预后的差异(附427例报告)[J].临床泌尿外科杂志,2016,31(11):974-978.16.姬超岳#,钟文龙#,张雷,张雷,李学松*,方冬,郝瀚,熊耕砚,周利群*.上尿路上皮癌根治术后对侧上尿路复发危险因素分析[J].临床泌尿外科杂志,2016,31(11):965-968,973.17.鲍正清#,方冬#,岳才博,岳才博,蔡林,王天昱,李学松*,周利群*.原发性阴茎阴囊Paget病22例临床分析[J].北京大学学报(医学版),2016,48(4):638-642.18.张雷,邓文涛,李学松*,等.高度怀疑恶性前列腺肿物6针法穿刺临床分析[J].现代泌尿外科杂志,2016,21(10):786-789.19.彭鼎#,李学松#,张崔建,等.T3N0M0期肾细胞癌患者预后相关因素分析:单中心182例患者回顾性研究[J].北京大学学报(医学版),2016,48(5):806-811.20.张华俊#,唐世英#,张中元,唐琦,李学松*,周利群*.肾部分切除术术前肾周脂肪粘连的评估[J].现代泌尿外科杂志,2016,21(9):727-729.21.钟文龙,杨昆霖,李学松*,等.回肠代输尿管术治疗双侧长段输尿管损伤一例报告并文献复习[J].中华泌尿外科杂志,2016,37(8):599-60222.李学松,钟文龙,吴帅,等.回肠代输尿管术临床应用及手术技巧(附光盘)[J].现代泌尿外科杂志,2016,21(4):245-248.DOI:10.3969/j.issn.1009-8291.2016.04.001.23.余霄腾,张崔建,李学松*,等.索拉非尼治疗晚期肾癌患者的疗效及不良反应[J].现代泌尿外科杂志,2016,21(6):437-440.24.曹振朋,刘瑾,李学松*.马兜铃酸相关尿路上皮癌研究进展[J].中华泌尿外科杂志,2015,36(8):638-640.25.李学松*,刘沛.腹腔镜及开放根治性膀胱全切-回肠原位新膀胱术的比较及应用体会[J].中华腔镜泌尿外科杂志(电子版),2015,(2):81-85.26.郭刚#,李学松#,张帆,等.索拉非尼治疗晚期肾癌所致手足皮肤反应与疗效的相关性研究[J].临床泌尿外科杂志,2015,30(10):893-896.27.杨昆霖,李学松*,周利群*.IUPU经腹腹腔镜联合膀胱软镜肾盂取石及肾盂成型术[J].泌尿外科杂志(电子版),2015,(3):4-6.28.刘沛,李学松*,周利群*.经腹完全腹腔镜肾输尿管全长切除术及改良膀胱袖状切除术:IUPU技术[J].泌尿外科杂志(电子版),2015,(3):10-12,6.29.唐琦,李学松*,周利群*.联合腹膜后及经腹入路腹腔镜治疗肾癌伴下腔静脉瘤栓[J].泌尿外科杂志(电子版),2015,(3):1-3.30.杨昆霖,李学松*,周利群*.IUPU经腹腹腔镜巨输尿管体外裁剪、乳头再植术[J].泌尿外科杂志(电子版),2015,(3):7-9.31.李学松,周利群*,唐琦,等.联合后腹腔及经腹入路腹腔镜技术在肾癌伴下腔静脉瘤栓患者中的应用[J].北京大学学报(医学版),2015,47(4):569-570.32.吴鑫,刘沛,朱雨泽,郑卫,唐琦,姚林,张崔建,郝瀚,李学松*,周利群.腹腔镜与开放根治性膀胱全切-回肠原位新膀胱术的疗效对比[J].现代泌尿外科杂志,2015,(4):229-233.33.李学松,杨昆霖,周利群.IUPU经腹腹腔镜肾盂成型术治疗成人肾盂输尿管连接处梗阻(附视频)[J].现代泌尿外科杂志,2015,(6):369-372.34.刘沛#,吴鑫#,朱雨泽,唐琦,方冬,李学松*,郝金瑞,周利群*.回肠代输尿管术治疗医源性长段输尿管损伤[J].北京大学学报(医学版),2015,47(4):643-647.35.刘沛,李学松*.嗜铬细胞瘤应行腹腔镜手术治疗[J].现代泌尿外科杂志,2014,19(10):683-685.36.张雷,李学松*.T1b期肾癌应选择肾根治术[J].现代泌尿外科杂志,2014,(12):821-822.DOI:10.3969/j.issn.1009-8291.2014-12-016.37.周亮亮,陈玉成,李学松*.膀胱嗜铬细胞瘤的诊治体会[J].首都医药,2014,(10):29-29,30.38.杨昆霖,李学松*,周利群*.经腹腹腔镜输尿管体外裁剪、乳头再植术治疗成人梗阻性巨输尿管症的方法[J].北京大学学报(医学版),2014,46(4):511-514.39.杨恺惟,张崔建,李学松*,等.小肾癌的临床病理特征:单中心1276例经验总结[J].北京大学学报(医学版),2014,46(5):790-793.40.康永明,方冬,李学松*,等.双侧上尿路尿路上皮癌30例临床诊疗分析[J].首都医科大学学报,2014,(3):290-294.41.刘沛,唐琦,李学松*,等.女性原发性尿道癌8例临床分析[J].现代泌尿外科杂志,2014,19(10):662-665,669.42.张雷,姚林,李学松*,等.经腹腹腔镜肾切除手术的肾蒂处理技术:单一术者191例经验总结[J].北京大学学报(医学版),2014,46(4):537-540.43.李学松.经腹腹腔镜肾癌根治术的肾蒂处理经验:手术技巧及出血性并发症的腔镜下处理(附视频)[J].现代泌尿外科杂志,2013,18(1):6-8,12.44.姚林,李学松*.肾脏小肿物的自然病程及诊治进展[J].中华泌尿外科杂志,2013,34(11):875-878.45.杨恺惟,李学松*,周利群.肾脏黏液小管状和梭形细胞癌一例并文献回顾[J].中华临床医师杂志(电子版),2013,(8):3652-3654.DOI:10.3877/cma.j.issn.1674-0785.2013.08.080.46.方冬,李学松*.腹腔镜上尿路手术经腹腔途径更有优势[J].现代泌尿外科杂志,2013,18(2):183-185.DOI:10.3969/j.issn.1009-8291.2013.02.028.47.郑卫,汤坚强,李学松*.盆腔胸膜外孤立性纤维性肿瘤一例报告[J].中华泌尿外科杂志,2013,34(1):77.DOI:10.3760/cma.j.issn.1000-6702.2013.01.026.48.吴翔,李涛,李学松*.肾脏平滑肌瘤5例分析并文献回顾[J].现代泌尿外科杂志,2013,18(4):398-400.DOI:10.3969/j.issn.1009-8291.2013.04.033.49.杨飞亚,姚林,李学松*,等.腹腔镜双侧腹股沟淋巴结清扫术一例并文献复习[J].中华临床医师杂志(电子版),2013,(6):2696-2698.50.邵光军,蔡林,李学松*,等.脐尿管癌:单中心30年经验总结[J].北京大学学报(医学版),2013,45(5):774-778.51.唐琦,杨恺惟,郝翰,李学松*,周利群*.腹腔镜治疗双肾被膜下积液致Page肾一例及文献回顾[J].中华临床医师杂志(电子版),2013,(3):1278-1280.52.方冬#,杨恺惟#,李学松*,等.腹腔镜治疗大体积肾癌的临床经验及与开放手术的比较[J].现代泌尿外科杂志,2013,18(6):553-556.53.方冬,李学松*,谌诚,等.经腹腔与腹膜后腹腔镜肾癌根治术疗效比较[J].现代泌尿外科杂志,2013,18(2):126-129..54.杨恺惟#,方冬#,李学松*,等.腹腔镜下不同手术入路治疗大体积肾癌的效果比较[J].中华临床医师杂志(电子版),2013,(21):9458-9461.55.王天昱,陈晓鹏,李学松*,等.前列腺癌近距离治疗的效果和不良反应分析[J].现代泌尿外科杂志,2013,18(4):322-328.56.吴翔,李涛,高祥勋,李学松*.肾脏肿瘤穿刺活检病理分型与组织学分级诊断准确性分析[J].中华临床医师杂志(电子版),2012,06(15):4185-4189.57.李子然,李学松*.关于包皮环切术的争议[J].中华临床医师杂志(电子版),2012,6(18):140-143.58.张中元,李学松*,周利群*.肾脏肿瘤评分系统的研究新进展[J].微创泌尿外科杂志,2012,1(1):20-23.59.申海涛,郝瀚,连庆文,李学松*,周利群.后腹腔镜下离断式肾盂成形术48例治疗体会[J].中华临床医师杂志(电子版),2012,06(15):4454-4455.60.吴翔,李学松*,何志嵩*,周利群.舒尼替尼治疗转移性肾癌的进展[J].中华临床医师杂志(电子版),2012,6(3):655-658.61.张中元,唐琦,李学松*,等.R.E.N.A.L.肾肿瘤评分系统用于保留肾单位手术的临床分析[J].北京大学学报(医学版),2012,44(4):539-543.62.郑卫,吴鑫,张雷,宋刚,张争,龚侃,宋毅,李学松*,何志嵩*,周利群.腹腔镜膀胱全切手术:单中心60例学习曲线结果分析[J].北京大学学报(医学版),2012,44(4):558-562.63.胡佩胜,何睿,杨新宇,李学松*,周刊群,何志嵩,郭应禄.腹腔镜治疗精囊囊性神经鞘瘤一例并文献回顾[J].中华临床医师杂志(电子版),2012,6(3):714-715.64.毕金文,周亮亮,李学松*,等.后肾腺瘤的临床及病理分析并文献复习[J].中华临床医师杂志(电子版),2011,05(3):868-870.65.王天昱,陈晓鹏,李学松*,等.前列腺特异性抗原和Gleason评分对前列腺癌患者核素骨扫描结果的预测价值[J].北京大学学报(医学版),2012,44(4):528-534.66.陈晓鹏,汤坚强,李学松*,等.回肠代输尿管术治疗长段输尿管缺损一例报道并文献复习[J].中华临床医师杂志(电子版),2011,05(8):2410-2413.67.刘荣耀,赵鹏举,李学松*,等.经腹腔完全腹腔镜肾输尿管全长切除术治疗上尿路尿路上皮癌[J].北京大学学报(医学版),2011,43(4):531-534.68.谌诚,周亮亮,李学松*,等.嗜铬细胞瘤诊疗:单中心142例报告[J].中华泌尿外科杂志,2011,32(1):35-37.69.吴翔,于楠,高莹,李学松*,等.舒尼替尼致转移性肾细胞癌患者甲状腺功能异常的临床分析[J].中华临床医师杂志(电子版),2011,05(3):659-662.DOI:10.3877/cma.j.issn.1674-0785.2011.03.005.70.张崔建,杨新宇,李学松*,等.肾脏非成熟囊性畸胎瘤一例报道及文献回顾[J].中华临床医师杂志(电子版),2010,04(12):2563-2566.DOI:10.3877/cma.j.issn.1674-0785.2010.12.042.71.荣建红,张岩,李学松*,等.泌尿系子宫内膜异位症的诊断及治疗(附22例报告)[J].北京大学学报(医学版),2010,42(4):461-464.DOI:10.3969/j.issn.1671-167X.2010.04.023.72.李学松,宋毅,龚侃,等.舒尼替尼治疗转移性肾脏透明细胞癌的临床研究[J].中华外科杂志,2010,48(5):375-377.DOI:10.3760/cma.j.issn.0529-5815.2010.05.015.73.李学松,龚侃,孙国锋,等.Bcl-2和Bax在前列腺癌不同周期时相的表达[J].中华外科杂志,2008,46(10):768-771.DOI:10.3321/j.issn:0529-5815.2008.10.013.74.李日清,李学松*,张祥华,等.原发性附睾肿瘤——附42例报告[J].中华临床医师杂志(电子版),2007,1(7):14-17.DOI:10.3969/j.issn.1674-0785.2007.07.006.75.李学松,李淑清,何志嵩,等.射频消融治疗肾肿瘤[J].中华临床医师杂志(电子版),2007,1(7):7-10.DOI:10.3969/j.issn.1674-0785.2007.07.003.76.李学松,李日清,张祥华,等.腹腔镜在苗勒管持续存在综合征诊断治疗中的应用——病例报告附录像[J].中华临床医师杂志(电子版),2007,1(7):50-51.DOI:10.3969/j.issn.1674-0785.2007.07.017.77.李学松,周利群,何志嵩,等.聚集素在前列腺癌细胞不同周期时相的表达[J].中华泌尿外科杂志,2006,27(1):36-39.78.李学松,厉将斌,梁云燕,等.紫龙金联合雌二醇氮芥对小鼠前列腺癌体内抑瘤作用的研究[J].中华泌尿外科杂志,2005,26(12):803-805.79.李学松,肖云翔,周利群,等.成人前列腺囊高分化鳞癌一例[J].中华外科杂志,2005,43(2):135.80.李学松,白龙伟,陈捷,等.肾脏平滑肌瘤三例报告[J].中华泌尿外科杂志,2004,25(10):675.81.李学松,梁云燕,王代树,等.紫龙金对前列腺癌细胞系DU-145的体外作用[J].中华实验外科杂志,2004,21(6):720-722.82.李学松,梁云燕,王代树,等.复方中药紫龙金对前列腺癌的体外作用[J].中华泌尿外科杂志,2004,25(8):516-520.83.李学松,梁云燕,王代树,等.复方中药紫龙金对前列腺癌细胞系LNCaP的体外作用[J].中国中西医结合杂志,2004,24(7):621-624.84.李学松,何志嵩*.激素难治性前列腺癌治疗进展[J].中国肿瘤,2003,12(12):699-703....

擅长:   复杂疑难的泌尿系肿瘤以及上尿路修复的腔镜及开放手术。包括:腹腔镜肾脏部分切除术,腹腔镜肾癌根治术+淋巴结清扫,经腹完全腹腔镜肾输尿管全长切除术,腹腔镜及开放保留神经前列腺癌根治术,膀胱肿瘤电切术,膀胱癌根治术+盆腔淋巴结清扫术+回肠原位新膀胱术,腹腔镜和开放手术治疗输尿管疾病(包括输尿管长段缺损的肠代输尿管术),晚期肾癌靶向药物治疗。

  • 推荐医院
  • 医院文章